Canine Atopic Dermatitis Market Growth, Size, Trends Analysis - By Product, By Type, By Mode of Administration, By Indication, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Canine Atopic Dermatitis Market Introduction and Overview

According to SPER market research, 'Global Canine Atopic Dermatitis Market Size- By Product, By Type, By Mode of Administration, By Indication, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Canine Atopic Dermatitis Market is predicted to reach 13.91 billion by 2034 with a CAGR of 10.84%.

Canine atopic dermatitis is a long-term skin condition in dogs that is driven by an allergic reaction to environmental allergens, such as pollen, mites, molds, and certain foods. This condition is genetically influenced, engaging the immune system, and leads to excessive pruritus, erythema, and skin infections. Onset typically occurs between six months and three years of age, with clinical symptoms including continual scratching, licking, ear infections, and hair loss.

Restraints: The market is subject to strict regulatory standards that can influence its growth. Regulatory authorities have notably heightened their attention on confirming the safety and effectiveness of veterinary drugs, including those prescribed for treating canine atopic dermatitis. Such scrutiny can pose significant challenges for market players, as new medications are required to pass comprehensive approval processes prior to importation across borders.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Type, By Mode of Administration, By Indication, By Distribution Channel

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Zoetis Services LLC, Merck & Co., Inc, Elanco, Boehringer Ingelheim International GmbH, Virbac, Vetoquinol, Dechra, Biofelix Pharma Group, TORAY INDUSTRIES, INC, Bioiberica S.A.U.

Global Canine Atopic Dermatitis Market Segmentation:

By Product: Based on the Product, Global Canine Atopic Dermatitis Market is segmented as; Glucocorticoids, Antihistamines, Immunosuppressants, Mabs, Others.

By Type: Based on the Type, Global Canine Atopic Dermatitis Market is segmented as; Prescription, OTC.

By Mode of Administration: Based on the Mode of Administration, Global Canine Atopic Dermatitis Market is segmented as; Oral, Topical, Injectable.

By Indication: Based on the Indication, Global Canine Atopic Dermatitis Market is segmented as; Ectoparasites, Food Allergy, Allergic skin infections, Others.

By Distribution Channel: Based on the Distribution Channel, Global Canine Atopic Dermatitis Market is segmented as; Veterinary Hospitals/Clinics, Retail, E-commerce.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25249

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER internal database
- 2.1.4. Premium insight from KOL
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Canine Atopic Dermatitis Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Canine Atopic Dermatitis Market

7. Global Canine Atopic Dermatitis Market, By Product (USD Million) 2021-2034

7.1. Glucocorticoids
7.2. Antihistamines
7.3. Immunosuppressants
7.4. MAbs
7.5. Others

8. Global Canine Atopic Dermatitis Market, By Type (USD Million) 2021-2034

8.1. Prescription
8.2. OTC

9. Global Canine Atopic Dermatitis Market, By Mode of Administration (USD Million) 2021-2034

9.1. Oral
9.2. Topical
9.3. Injectable

10. Global Canine Atopic Dermatitis Market, By Indication (USD Million) 2021-2034

10.1. Ectoparasites
10.2. Food Allergy
10.3. Allergic skin infections
10.4. Others

11. Global Canine Atopic Dermatitis Market, By Distribution Channel (USD Million) 2021-2034

11.1. Veterinary Hospitals/Clinics
11.2. Retail
11.3. E-commerce

12. Global Canine Atopic Dermatitis Market, (USD Million) 2021-2034

12.1. Global Canine Atopic Dermatitis Market Size and Market Share

13. Global Canine Atopic Dermatitis Market, By Region, (USD Million) 2021-2034

13.1. Asia-Pacific
- 13.1.1. Australia
- 13.1.2. China
- 13.1.3. India
- 13.1.4. Japan
- 13.1.5. South Korea
- 13.1.6. Rest of Asia-Pacific
13.2. Europe
- 13.2.1. France
- 13.2.2. Germany
- 13.2.3. Italy
- 13.2.4. Spain
- 13.2.5. United Kingdom
- 13.2.6. Rest of Europe
13.3. Middle East and Africa
- 13.3.1. Kingdom of Saudi Arabia
- 13.3.2. United Arab Emirates
- 13.3.3. Qatar
- 13.3.4. South Africa
- 13.3.5. Egypt
- 13.3.6. Morocco
- 13.3.7. Nigeria
- 13.3.8. Rest of Middle-East and Africa
13.4. North America
- 13.4.1. Canada
- 13.4.2. Mexico
- 13.4.3.United States
13.5. Latin America
- 13.5.1. Argentina
- 13.5.2. Brazil
- 13.5.3. Rest of Latin America

14. Company Profile

14.1. Zoetis Services LLC
- 14.1.1. Company details
- 14.1.2. Financial outlook
- 14.1.3. Product summary
- 14.1.4. Recent developments
14.2. Merck & Co., Inc
- 14.2.1. Company details
- 14.2.2. Financial outlook
- 14.2.3. Product summary
- 14.2.4. Recent developments
14.3. Elanco
- 14.3.1. Company details
- 14.3.2. Financial outlook
- 14.3.3. Product summary
- 14.3.4. Recent developments
14.4. Elanco
- 14.4.1. Company details
- 14.4.2. Financial outlook
- 14.4.3. Product summary
- 14.4.4. Recent developments
14.5. Virbac
- 14.5.1. Company details
- 14.5.2. Financial outlook
- 14.5.3. Product summary
- 14.5.4. Recent developments
14.6. Vetoquinol
- 14.6.1. Company details
- 14.6.2. Financial outlook
- 14.6.3. Product summary
- 14.6.4. Recent developments
14.7. Dechra
- 14.7.1. Company details
- 14.7.2. Financial outlook
- 14.7.3. Product summary
- 14.7.4. Recent developments
14.8. Biofelix Pharma Group
- 14.8.1. Company details
- 14.8.2. Financial outlook
- 14.8.3. Product summary
- 14.8.4. Recent developments
14.9. TORAY INDUSTRIES, INC
- 14.9.1. Company details
- 14.9.2. Financial outlook
- 14.9.3. Product summary
- 14.9.4. Recent developments
14.10. Bioiberica S.A.U
- 14.10.1. Company details
- 14.10.2. Financial outlook
- 14.10.3. Product summary
- 14.10.4. Recent developments
14.11. Others